Calcimimetic Prescriptions in Fee-for-Service Medicare Beneficiaries Undergoing Dialysis.

ABSTRACT:

Importance

Calcimimetics are a mainstay of treatment for secondary hyperparathyroidism (sHPT), a ubiquitous condition in end-stage kidney disease (ESKD) associated with fractures, cardiovascular events, and mortality. In 2018, Medicare implemented the Transitional Drug Add-On Payment Adjustment (TDAPA), which shifted calcimimetic coverage from Part D prescription drug plans to Part B. Prior to TDAPA, Medicare beneficiaries with ESKD faced varying out-of-pocket costs for calcimimetics at the point of pharmacy depending on presence and magnitude of low-income subsidies (LISs). TDAPA differentially alleviated barriers to filling these costly medications.

Objective

To assess whether calcimimetic prescriptions increased post-TDAPA among patients subject to high out-of-pocket cost

SUBMITTER: Caldwell JS 

PROVIDER: S-EPMC12008760 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature